Cell Expansion Market Size, Share & Industry Analysis, By Product Type (Instruments & Equipment, Consumables, and Software & Services), By Technology (Adherent Cell Expansion Technologies, Suspension Cell Expansion Technologies, Automated & Closed Systems, and Others), By Cell Type (Stem Cells, Immune Cells, & Differentiated Cells), By Application (Cell Therapy & Regenerative Medicine, Biopharmaceutical Production, Drug Discovery & Development, and Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes & Others), and Regional Forecast, 2026-2034

The global cell expansion market size was valued at USD 22.14 billion in 2025. The market is projected to grow from USD 24.82 billion in 2026 to USD 54.04 billion by 2034, exhibiting a CAGR of 10.22% during the forecast period.

The market is anticipated to witness a noteworthy growth trajectory during the forecast period. Cell expansion is a process of growing and multiplying living cells in controlled laboratory conditions, primarily for therapeutic, research, and industrial applications. Furthermore, the increasing development of cell-based therapies, tissue engineering, drug discovery, and bio manufacturing is leading to the adoption of products, thereby driving market growth.

• For instance, in June 2025, Celltrio secured USD 5.0 million investment for advancing automation solutions for cell culturing and cell & gene therapy.

The major players in the market include Thermo Fisher Scientific Inc., and Cytiva with a robust portfolio and strategic activities, supporting the dominance of these companies in the market.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Chronic Diseases and Growing Adoption of Cell & Gene Therapies to Propel the Market Growth

The significant driver fueling the growth of the market is the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and genetic conditions. The rising number of cases has heightened the demand for innovative and effective treatment options beyond traditional therapies. 

The increasing focus of key players on offering advanced cell and gene therapies to improve the management of chronic conditions is expected to propel the global cell expansion market growth.

• For instance, in December 2023, Vertex Pharmaceuticals Incorporated collaborated with CRISPR Therapeutics and received the U.S. FDA approval for CASGEVY, a CRISPR/Cas9 genome-edited cell therapy. It is used for treating Sickle Cell Disease (SCD) in patients aged 12 years and above with recurrent VOCs (vaso-occlusive crises). 

MARKET RESTRAINTS

High Cost of GMP-Grade Cell Expansion to Restrict the Market Growth

The high cost associated with GMP-grade cell expansion presents a significant restraint to market growth. The specialized facilities, stringent quality controls, and advanced technology increase overall production expenses. Additionally, it limits the affordability and accessibility of GMP-grade cells for many biotech and pharmaceutical companies, thereby impeding market growth.

• For instance, in September 2022, the report summarized the costs associated with preparing human pluripotent stem cell lines for use in cell therapy manufacturing. Avda Biotechnology Ltd, Israel, stated that the process from R&D to GMP manufacturing takes three times longer than the initial development phase and increases the cost by approximately USD 3.0 million.

MARKET OPPORTUNITIES

Emergence of Allogenic Cell Therapies to Create Lucrative Growth Opportunities

Currently, autologous approaches are used for cell therapy and regenerative medicine that use the patient's own cells for treatment, but their effectiveness can be limited by cell quality or quantity, especially in older or ill patients. Thus, the emergence of allogenic cell therapies offers lucrative growth opportunities as these methods utilize donor cells, enabling scalable and more cost-effective production processes. 

Moreover, this advancement accelerates the development of off-the-shelf treatments for various diseases, including cancer and degenerative disorders. Additionally, many key players are fplatlfocusing on launching new platforms for allogenic manufacturing to boost the market growth.

• For instance, in January 2024, Getinge collaborated with CellRev to develop Livit ACE (Adherent Cell Expansion), a device used for allogenic cell therapy manufacturing.

CELL EXPANSION MARKET TRENDS

Integration of AI in Instruments to Support the Market Growth

The increasing integration of AI in cell expansion for faster and accurate cell handling, to optimize drug discovery and cell research, is a key market trend.

• For instance, in November 2024, Yamaha Motor Co., Ltd. planned to launch CELL HANDLER(TM) 2 in March 2025. It is an advanced cell picking and imaging system designed to improve research efficiency in drug development. It offers faster, more accurate cell handling, enhanced imaging, AI-driven automation, and improved usability for cell research, thereby supporting scientists in making discoveries.

MARKET CHALLENGES

Limited Availability of Skilled Personnel to Challenge Market Growth

One of the factors challenging the market growth is the scarcity of trained professionals. The cell expansion involves complex laboratory procedures that demand specialized knowledge and technical skills. The limited availability of skilled personnel may also restrict the adoption and scaling of cell-based research and analysis within research institutions and clinical laboratories.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type 

Recurrent Usage and Product Launches Associated with Consumables to Propel Consumables Segmental Growth

By product type segmentation, the market is divided into instruments & equipment, consumables, and software & services.

To know how our report can help streamline your business, Speak to Analyst

The consumables segment held a dominant cell expansion market share in 2025. The growth of the segment is driven by the recurring use of media, sera, reagents, growth factors, microcarriers, and single-use bioprocess bags for cell expansion procedures.

• For instance, in September 2022, denovoMATRIX GmbH launched animal component-free product lines at Cell Therapy Grade (CTG) consumables. This product is designed for stem cell therapy manufacturing.

The instruments & equipment segment is expected to grow at a CAGR of 8.82% over the forecast period.

By Technology

Increasing Adoption and Convenience Bolster the Adherent Cell Expansion Technologies Segment Growth

In terms of technology, the market is categorized into adherent cell expansion technologies, suspension cell expansion technologies, automated & closed systems, and others. 

The adherent cell expansion technologies segment held the maximum market share in 2025 with a 41.9% share. The growth of this segment is driven by the adoption of this technology in early-stage research, stem cell studies, and regenerative medicine applications.

• For instance, in July 2024, Green Elephant Biotech GmbH designed and launched the CellScrew system, a space-efficient adherent-cell cultivation system. It is designed to provide a large surface area for adherent cells while offering ease of handling and culture-scale flexibility. 

The automated & closed systems segment is expected to grow at a CAGR of 13.63% over the forecast period.

By Cell Type

Increasing Development of Stem Cells-Based Therapies to Boost the Stem Cells Segment’s Growth

Based on cell type, the market is categorized into stem cells, immune cells, differentiated cells, and others.

By cell type, the stem cells segment held the maximum market share in 2025. The segment held a share of 36.8% in 2025. The growth of the segment is attributed to the increasing prevalence of chronic diseases and the rising development of stem cell-based therapies.

• For instance, in July 2024, Bioserve India launched advanced stem cell products for REPROCELL in India. 

The immune cells segment is set to flourish with a growth rate of 13.71% during the forecast period. 

By Application

Rising Product Launches for Biopharmaceutical Manufacturing Purposes to Boost the Biopharmaceutical Production Segment Growth

Based on application, the market is segmented into cell therapy & regenerative medicine, biopharmaceutical production, drug discovery & development, and others.

The biopharmaceutical production segment held the dominating position in 2025. The segment held a 41.9% share in 2025. The rising prevalence of chronic diseases and the focus of biopharmaceutical companies and industries on developing cell-based therapies for various diseases, such as oncology, autoimmune disorders, genetic diseases, and metabolic disorders, drive segment growth.

• For instance, in August 2024, PHC Corporation showcased an innovative cell expansion system, LiCellGrow, at the upcoming ISCT Europe 2024. The system aimed to enable pharmaceutical companies to monitor metabolic changes in cells in real-time and automatically adjust culture conditions to enhance cell growth. 

The cell therapy & regenerative medicine segment is set to flourish with a growth rate of 12.58% over the forecast period. 

By End User

Increasing Investments and Research Activities to Boost the Pharmaceutical & Biotechnology Companies Segment Growth

Based on end user, the market is segmented into cell therapy & regenerative medicine centers, academic & research institutes, pharmaceutical & biotechnology companies, and others. 

In 2025, the pharmaceutical & biotechnology companies segment is expected to witness a leading growth trajectory. The segment held a 45.2% share in 2025. The rising drug discovery and development, increasing investment for research, and expanding product offerings are expected to boost the adoption of these products in these settings.

• For instance, in October 2025, Lonza Group AG launched TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium. The additions are aimed at broadening the company’s cell and gene therapy portfolio.

In addition, academic & research institutes segment is poised to expand at a CAGR of 7.51% during the forecast period. 

Cell Expansion Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa. 

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the leading share in 2024, valued at USD 10.18 billion, and maintained its leading position in 2025, with a valuation of USD 11.47 billion. The dominant share of North America is due to the presence of major players with advanced product offerings and high-end research infrastructure. In 2025, the U.S. market reached USD 10.91 billion. 

The U.S. is expected to dominate the North America region's market. The rising research activities, presence of key players, and funding environment are expected to boost the market growth in the country.

• In November 2024, Ro IamFluidics B.V. introduced a new research-grade dissolvable microcarrier for adherent cell culturing. It is used for streamline and scaled-up processes for biologics manufacturing, advanced cell therapies, and cultured meat production.

Europe and Asia Pacific

Regions such as the Asia Pacific and Europe are likely to witness significant growth in the coming years. During the forecast period, the European region is projected to record a growth rate of 10.00%, which is the second highest among all the regions, and touch the valuation of USD 6.40 billion in 2026. This growth is primarily driven by the increasing research and development for cell-based therapies and the presence of key players in the market with advanced product offerings. Backed by these factors, the U.K. recorded a valuation of USD 1.25 billion, Germany USD 1.16 billion, and France USD 0.91 billion in 2025. After Europe, the Asia Pacific market reached a valuation of USD 3.52 billion in 2025 and emerged as the third-largest region in the global market. In the region, India and China captured the valuation of USD 0.62 and USD 0.64 billion in 2025. 

Latin America and the Middle East & Africa

The Middle East & Africa and Latin America regions are expected to witness moderate growth in this market over the forecast period. The Latin America market, in 2025, recorded a valuation of USD 0.89 billion. Increasing focus of key players to shift their presence in the region is anticipated to boost the market growth, but at a slower rate. In the Middle East & Africa, the GCC attained the value of USD 0.26 billion in 2025. 

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Players’ Expansion of Product Offering and Strong Research and Development Activities to Maintain their Positions

The market shows a fragmented structure with a large number of companies actively operating across the globe.

Thermo Fisher Scientific Inc., Danaher Corporation, and Sartorius are some of the dominating players in the market. Expanded product portfolio and new advanced product launches is to boost their position in the market.

Apart from this, other prominent players in the market include Corning Incorporated, BD, and Lonza Group, among other major players in the market. These key players are focusing on offering various products such as instruments, consumables, and services to enhance their market presence.

LIST OF KEY CELL EXPANSION COMPANIES PROFILED:

• Thermo Fisher Scientific Inc. (U.S.)
• Danaher Corporation (U.S.)
• Sartorius AG (Germany)
• Merck KGaA (Germany)
• Lonza Group (Switzerland)
• Corning Incorporated (U.S.)
• BD (U.S.)
• Terumo Corporation (Japan)
• Miltenyi Biotec (Germany)
• Eppendorf SE (Germany)

KEY INDUSTRY DEVELOPMENTS

• September 2025: Sartorius AG expanded its manufacturing facility in Illkirch, near Strasbourg. The facility manufactured transfection reagents for developing and producing cell and gene therapies.
• August 2025: Danaher Corporation (Cytiva) in collaboration with Culture Biosciences included cloud-connected bioreactor technology to accelerate the future of digital bioprocessing.
• March 2025: Danaher Corporation (Cytiva) announced expansion of Xcellerex X-platform portfolio with the addition of 500-L and 2000-L bioreactors. The new offerings offered scientists and researchers an easy scale up for the manufacturing of next-generation advanced therapeutics.
• October 2024: Terumo Corporation announced the expansion of their presence in Latin America to support automated manufacturing solutions for cell and gene therapy companies in Brazil, Colombia, and Mexico.
• October 2023: Terumo Corporation and BioCentriq collaborated for the next phase demonstration of Terumo BCT's automated cell and gene therapy platforms to accelerate CAR-T cell development.

REPORT COVERAGE 

The market analysis provides an in-depth study of the market size and forecast for all the market segments included in the report. The market report also comprises new product launches, key industry developments, and details on partnerships, mergers, and acquisitions. The report also gives an overview of technological advancements in the market, including details on the market dynamics and market trends, and market opportunities. Moreover, the market research report also encompasses a detailed competitive landscape with information on the market share and profiles of key operating players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation